Pharma News

Malignant brain tumor is new medical concern due to wi-fi and Cell Phone use

New studies escalate medical concerns about glioma (a malignant brain tumor) from cell phone use. The BioInitiative Working Group (BWG) noted that evidence for health risk from wireless technology is growing stronger and require immediate action. The Group released a mid-year update covering new science studies from 2012 to 2014.

Elbrit Life Sciences dreaming Big on Indian Pharmaceutical Business

‘Elbrit Life Sciences’, a new pharmaceutical company based in Mumbai, India, today opened gates for business in India. The company would be serving the South Indian states initially and aims to cover the entire country with time. According to the sources, the company would be targeting cardiac and diabetes product segments in the present year. Elbrit Life Sciences is a part of a global business group based in UK with investments in science, research and education. The group has significantly invested in next generation healthcare such as genetic therapy, molecular biology, DNA mapping and biomarkers. The group also owns world renowned scientific and academic publishing brands.

Guidelines for Hepatitis C treatment issued by WHO

World Health Organization (WHO) has issued its first guidance for the treatment of hepatitis C which affects an estimated 130 million to 150 million people and results in 3,50,000 to 5,00,000 deaths a year.
The "WHO Guidelines for the screening, care and treatment of persons with Hepatitis C infection" concurs the available effective and safer oral hepatitis medicines, along with the promise of even more new medicines in the next few years. 

Pfizer's two drugs significantly prolonged progression of tumor with Advanced Breast Cancer

Combination of Palbociclib with Letrozole significantly prolonging progression of tumor compared with single letrozole in post-menopausal women with estrogen receptor positive. This details resulted from PALOMA-1 study which is a Phase 2 trial designed to assess progression-free survival in post-menopausal women with ER+, HER2- advanced breast cancer receiving palbociclib in combination with letrozole versus letrozole alone.

Pages